Nantahala Capital Administration LLC boosted its place in OptiNose, Inc. (NASDAQ:OPTN – Free Report) by 442.3% within the 2nd quarter, in keeping with the corporate in its most up-to-date Type 13F submitting with the Securities & Trade Fee. The fund owned 13,418,740 shares of the corporate’s inventory after shopping for an extra 10,944,444 shares throughout the quarter. OptiNose makes up about 0.8% of Nantahala Capital Administration LLC’s funding portfolio, making the inventory its sixteenth largest holding. Nantahala Capital Administration LLC owned roughly 8.90% of OptiNose value $14,425,000 on the finish of the newest reporting interval.
A number of different institutional traders and hedge funds have additionally not too long ago purchased and offered shares of the corporate. Kingdon Capital Administration L.L.C. boosted its holdings in OptiNose by 5.4% within the fourth quarter. Kingdon Capital Administration L.L.C. now owns 3,899,237 shares of the corporate’s inventory value $5,030,000 after buying an extra 200,000 shares throughout the interval. HighMark Wealth Administration LLC acquired a brand new place in shares of OptiNose within the 1st quarter valued at about $36,000. Easterly Funding Companions LLC grew its place in shares of OptiNose by 34.0% throughout the 1st quarter. Easterly Funding Companions LLC now owns 2,038,039 shares of the corporate’s inventory valued at $2,976,000 after shopping for an extra 516,730 shares over the last quarter. Vanguard Group Inc. raised its stake in OptiNose by 1.5% throughout the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the corporate’s inventory value $6,194,000 after buying an extra 62,906 shares throughout the interval. Lastly, Oracle Funding Administration Inc. purchased a brand new place in OptiNose within the first quarter value about $474,000. Institutional traders and hedge funds personal 85.60% of the corporate’s inventory.
OptiNose Inventory Down 4.1 %
Shares of OPTN inventory opened at $0.67 on Tuesday. The corporate has a market cap of $75.74 million, a P/E ratio of -2.48 and a beta of -0.04. The enterprise has a 50 day shifting common of $0.94 and a two-hundred day shifting common of $1.10. OptiNose, Inc. has a 52 week low of $0.67 and a 52 week excessive of $2.10.
OptiNose (NASDAQ:OPTN – Get Free Report) final launched its quarterly earnings knowledge on Thursday, August eighth. The corporate reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The agency had income of $20.49 million throughout the quarter, in comparison with analyst estimates of $20.81 million. Analysts count on that OptiNose, Inc. will submit -0.22 EPS for the present fiscal yr.
Insider Exercise at OptiNose
In different OptiNose information, CEO Ramy A. Mahmoud offered 111,426 shares of the enterprise’s inventory in a transaction on Wednesday, July seventeenth. The inventory was offered at a median value of $1.14, for a complete transaction of $127,025.64. Following the completion of the transaction, the chief govt officer now owns 1,206,978 shares within the firm, valued at roughly $1,375,954.92. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which is accessible at this hyperlink. In different information, CEO Ramy A. Mahmoud offered 111,426 shares of the corporate’s inventory in a transaction that occurred on Wednesday, July seventeenth. The shares have been offered at a median value of $1.14, for a complete worth of $127,025.64. Following the completion of the sale, the chief govt officer now instantly owns 1,206,978 shares of the corporate’s inventory, valued at roughly $1,375,954.92. The sale was disclosed in a doc filed with the SEC, which is accessible at this hyperlink. Additionally, insider Michael F. Marino III offered 49,408 shares of the inventory in a transaction that occurred on Wednesday, July seventeenth. The shares have been offered at a median value of $1.14, for a complete transaction of $56,325.12. Following the completion of the transaction, the insider now owns 550,464 shares of the corporate’s inventory, valued at $627,528.96. The disclosure for this sale might be discovered right here. Insiders have offered a complete of 167,679 shares of firm inventory value $191,154 within the final three months. 2.70% of the inventory is owned by firm insiders.
OptiNose Profile
OptiNose, Inc, a specialty pharmaceutical firm, focuses on the event and commercialization of merchandise for sufferers handled by ear, nostril, throat, and allergy specialists in the USA. The corporate gives XHANCE, a therapeutic product using its proprietary exhalation supply system (EDS) that delivers a topically appearing corticosteroid for the therapy of persistent rhinosinusitis with nasal polyps, in addition to is in Part IIIb scientific trial for therapy of persistent sinusitis; and Onzetra Xsail, a powder EDS machine.
Additional Studying
Obtain Information & Rankings for OptiNose Day by day – Enter your e-mail tackle beneath to obtain a concise each day abstract of the newest information and analysts’ scores for OptiNose and associated corporations with MarketBeat.com’s FREE each day e-mail e-newsletter.